Watch for the Part B 12-month safety data from Study 302 (anticipated 2H26) and the female PHL topline data from Study 306 (1H27). The NDA submission timeline is the next key catalyst for FDA approval.
Price Chart
Executive Summary
Veradermics announced positive topline Phase 3 data for VDPHL01, an oral extended-release minoxidil, in male pattern hair loss. Study 304 met all primary and secondary endpoints with high statistical significance, showing robust hair count increases and early onset, with a favorable safety profile across >1,000 patients in two registration-directed studies. The results position VDPHL01 is positioned to become the first FDA-approved oral non-hormonal treatment for male pattern hair loss in nearly 30 years, with a potential best-in-indication option for the 50 million men in the U.S.
Key Facts
- Study 304 met all primary and secondary endpoints with high statistical significance (p<0.0001) in both QD and BID dosing arms.
- Mean increase in non-vellus TAHC at Month 6: 28.6 hairs/cm² (QD) and 36.4 hairs/cm² (BID) vs. 6.6 hairs/cm² for placebo.
- 55.7% (QD) and 68.7% (BID) of participants reported improved or much improved hair coverage on the AAIRS vs. 15.0% for placebo.
- Statistically significant separation from placebo on TAHC, PRO, and IGA as early as Month 2, the earliest time point measured.
- No treatment-related SAEs and no adverse events of special interest of cardiac origin observed.
- Combined placebo-controlled data from Studies 302 and 304 now reported for more than 1,000 male participants.
- HCP market research (n=198) showed 86% anticipate prescribing VDPHL01 in first 12 months if approved; HCPs expect Rx use for male PHL to double from 36% to 72%.
- Female pattern hair loss Phase 2/3 trial (Study 306 fully enrolled; topline data anticipated in first half of 2027.
Financial Impact
No financial data reported. The pattern hair loss market is projected to reach approximately $30 billion by 2028. HCP survey data suggests VDPHL01 could capture ~79% of male Rx volume if approved, doubling the current 36% Rx treatment rate.
Risk Factors
- Veradermics has no products approved for commercial sale and has incurred substantial losses since inception.
- Success depends entirely on FDA approval and commercialization of VDPHL01; regulatory delays or failure would materially harm the business.
- Competition from existing OTC and prescription treatments for pattern hair loss.
- Need for substantial additional financing to achieve goals.
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001827635-26-000036 |
| Document: a304acallslidesfinal130a.htm | 0001827635-26-000036 |
| Document: mane-20261019.htm | 0001827635-26-000036 |
| Document: 0001827635-26-000036-index-headers.html | 0001827635-26-000036 |
| Document: 0001827635-26-000036-index.html | 0001827635-26-000036 |
| Document: 0001827635-26-000036.txt | 0001827635-26-000036 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | 8-K | $122.28 $137.39 | ▲ +12.36% | ▲ +12.50% | $137.39 (+12.36%) |
Oct 13, 2026 13d ago | SC 13G | $116.26 $127.11 | ▲ +9.33% | ▲ +10.48% | $137.39 (+18.17%) |
Aug 21, 2026 9w ago | Insider Cluster | $98.46 $98.41 | ▲ +0.05% | ▲ +0.52% | $137.39 (−39.54%) |
Aug 20, 2026 9w ago | 3 | $102.82 $97.93 | ▼ −4.76% | ▼ −5.23% | $137.39 (+33.62%) |
Aug 18, 2026 9w ago | Insider Cluster | $111.23 $102.80 | ▼ −7.58% | ▼ −7.19% | $137.39 (+23.52%) |
Aug 11, 2026 10w ago | 8-K | $110.75 $111.31 | ▲ +0.51% | ▲ +0.91% | $137.39 (+24.05%) |
Aug 7, 2026 11w ago | S-1 | $110.75 $108.22 | ▲ +2.28% | ▲ +2.24% | $137.39 (−24.05%) |
Aug 7, 2026 11w ago | Institutional Cluster | $114.39 $112.71 | ▼ −1.47% | ▼ −1.87% | $137.39 (+20.11%) |
Jul 15, 2026 14w ago | 8-K | $123.70 $109.85 | ▼ −11.20% | ▼ −10.22% | $137.39 (+11.07%) |
May 12, 2026 23w ago | 8-K | $103.90 $100.38 | ▼ −3.39% | ▼ −3.47% | $137.39 (+32.23%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers